Yan Xie

382 posts

Yan Xie

Yan Xie

@Biostayan

Biostatistician, clinical epidemiologist

St Louis, MO Beigetreten Mart 2017
65 Folgt488 Follower
Yan Xie retweetet
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
What happens to the heart when people stop GLP-1 drugs? The short answer: nothing good. New from our team: a study of 330,000+ people in @BMJMedicine 🧵
Ziyad Al-Aly, MD tweet media
English
45
128
531
216.2K
Yan Xie retweetet
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
📢NEW: In a study of 600,000 people published today in @bmj_latest, we found GLP-1 drugs (Ozempic, Wegovy, Mounjaro) associated with reduced risk of addiction across alcohol, opioids, cocaine, cannabis, nicotine—and 50% fewer substance-related deaths. 🧵 bmj.com/content/392/bm…
Ziyad Al-Aly, MD tweet media
English
47
278
913
106.7K
Yan Xie retweetet
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
We have a big paper dropping at 23:30 GMT/6:30 PM ET. It's not about Long Covid, but I think it is one of the most important studies our team has done. For my Long Covid community: we are working very hard, we have a pipeline of projects, and new work is coming. My team and I are committed to this and will always show up for you. More at 6:30 ET.
English
33
95
737
18.3K
Yan Xie
Yan Xie@Biostayan·
We’re recruiting Postdoctoral Fellows (Clinical Epidemiology & Pharmacoepidemiology) ➡️ Details and application via Indeed: indeed.com/job/postdoctor… These positions are hired through our non-profit foundation.
English
0
0
1
90
Yan Xie retweetet
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
🚨 We're hiring Postdoctoral Fellows! 📷Join a high-performing team to tackle high-consequence public health questions — Long COVID, long-term health effects of acute infections, and more — using large-scale, high-quality databases + cutting-edge causal inference. Two exciting tracks: 🔹 Clinical Epidemiology 🔹 Pharmacoepidemiology Who's ready to make real-world impact? Details and application in link below📷 #EpiTwitter #Postdoc 👇
Ziyad Al-Aly, MD tweet media
English
1
13
31
4.1K
Yan Xie retweetet
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
Honored to speak at @Harvard’s Radcliffe Institute workshop on #LongCOVID. I am energized by our 2 days of brainstorming about the road ahead. The challenges are real, but I’m leaving hopeful. Millions living with Long Covid are counting on our progress—we must keep keep pushing forward. @AzolaAlba @meghanor
Ziyad Al-Aly, MD tweet media
English
45
75
602
25K
Yan Xie retweetet
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
It gets wilder. One of the researchers who is helping design this new generation of addictive foods is on GLP-1!!!!!!!
English
19
120
1.3K
107.4K
Yan Xie retweetet
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
For decades, the junk food industry has deliberately engineered foods to be addictive. Ozempic and other GLP-1 drugs have helped people break free from this cycle. In response, the industry is now searching for ways to counteract the effects of these medications, aiming to design foods that remain addictive even for those on GLP-1. Wild but true. Fascinating piece in NYTimes Magazine. buff.ly/40QHDnk
English
131
1.4K
5.6K
1.1M
Yan Xie retweetet
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
Thanks to @DKThomp for hosting me on his podcast. We talked about the GLP-1 and more. Details in this post below.
Derek Thompson@DKThomp

New ep: Are GLP-1s "the greatest medical breakthrough of the 21st century"? A new study of 2m Veterans Affairs patients with diabetes found GLP1 use was associated with a reduced risk of: - substance use disorders - psychotic disorders - Alzheimer's and dementia - clotting and heart attacks - infectious illnesses - several respiratory conditions To be blunt: WTAF is going on here? How did we turn synthesized Gila monster spit into a drug that seems to control diabetes, promote weight loss, and have such a absurdly wide range of positive effectiveness? Today we speak with @zalaly, an author of the new paper. What did his research look at? Why should we trust it? Where was the strongest signal? What new risks did we uncover? How on earth can a single drug do all of this? And how is it teaching us more deeply about "pleiotropic" medicine—single drugs that have a zillion unrelated positive side effects—and even the nature of willpower and free will in health? open.spotify.com/episode/0UtT3D…

English
0
3
26
4K
Yan Xie retweetet
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
🚨 ICYMI: Our latest study shows that the popular GLP-1 weight loss drugs (e.g. Ozempic) have broad health benefits — reducing risks of 42 health conditions. They are not without risks — increasing risks of of 19 health conditions. nature.com/articles/s4159…
English
0
14
43
2.9K
Yan Xie retweetet
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
To the community: A ‘yes’ to supporting Long Covid research is better than a ‘no.’ We will hold him to it—and I stand ready to work with him if he’s serious about advancing research and care for those impacted by Long Covid.
English
24
13
153
6.5K
Yan Xie retweetet
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
🚨 New from my team: In a study of over 2 million people, we comprehensively mapped the benefits and risks of GLP-1 (weight loss drugs) across 175 health conditions. 📄 Free access to the full study: rdcu.be/d6VYU 🧵 Explore the key findings: x.com/zalaly/status/…
Ziyad Al-Aly, MD@zalaly

1. What are the benefits and risks of GLP1? Our new study in @naturemedicine comprehensively maps all the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound). By @Biostayan, Taeyoung Choi and me 🧵 nature.com/articles/s4159…

English
7
30
148
13.4K

Entdecken

@bmj_latest @zalaly @BMJMedicine @Miao_Cai_SLU @statnews @ConversationUS @Harvard @AzolaAlba